Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Tiziana Life Sciences said it had commenced a clinical trial to test the safety and tolerability of a potential treatment for multiple sclerosis.
The so-called phase one clinical trial would test the Foralumab treatment and be led by Dr. Tanuja Chitnis at the Brigham and Women's Hospital, Harvard Medical School.
Successful demonstration of safety in the study would facilitate immediate evaluation of orally administered Foralumab in a phase two clinical study in patients with progressive multiple sclerosis.
At 8:30am: (LON:TILS) Tiziana Life Sciences Plc share price was +0.5p at 41.5p